Table 1.
Factors | Patient identification | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |
Age (years) | 51 | 74 | 49 | 94 | 51 | 66 | 72 | 57 | 51 | 84 |
Sex (male/female) | M | M | F | F | F | F | M | M | M | M |
Primary disease | Follicular lymphoma | Follicular lymphoma | Myasthenia gravis |
Myasthenia gravis Rheumatoid arthritis |
Kidney transplant | Kidney transplant | Kidney transplant | Liver transplant | Chronic myeloid leukemia | Chronic lymphocytic leukemia |
Other comorbidity | None | Hypertension | Thyrotoxicosis | Hypertension | Epilepsy | Hypertension |
Hypertension Diabetes mellitus |
Hypertension Diabetes mellitus Nephrotic syndrome |
None |
Diabetes mellitus Coronary heart disease |
COVID-19 vaccination | Yes | Yes | No | Yes | No | Yes | Yes | Yes | No | Yes |
Anti-CD20 antibody | Obinutuzumab |
Rituximab Obinutuzumab |
None | None | None | None | None | None | None | None |
Immunosuppressive agents for primary disease |
Cyclophosphamide Prednisolone |
Cyclophosphamide Prednisolone |
Tacrolimus |
Tacrolimus Prednisolone |
Tacrolimus Mycophenolate mofetil Everolimus Prednisolone |
Tacrolimus Mycophenolate mofetil Methylprednisolone |
Tacrolimus Mycophenolate mofetil Methylprednisolone |
Tacrolimus Mycophenolate mofetil Everolimus |
Iguratimod Tocilizumab Prednisolone |
Prednisolone |
Initial antiviral therapy Switched antiviral therapy |
Remdesivir |
Remdesivir Nirmatrelvir/Ritonavir |
Remdesivir Nirmatrelvir/Ritonavir |
Remdesivir Molnupiravir |
Remdesivir |
Remdesivir Nirmatrelvir/Ritonavir |
Remdesivir |
Remdesivir Nirmatrelvir/Ritonavir |
Remdesivir | Remdesivir |
Neutralizing antibody-based therapy |
Sotrovimab Casirivimab/Imdevimab |
Sotrovimab | Casirivimab/Imdevimab | Casirivimab/Imdevimab | Sotrovimab | Sotrovimab | Sotrovimab | Sotrovimab | Casirivimab/Imdevimab | Sotrovimab |
Initial Ct value | 18.6 | 19.8 | 25.3 | 18.2 | 19.6 | 25 | 17.9 | 22.4 | 15 | 25.6 |
Initial spike-specific antibody | Negative | Negative | 163 U/mL | Negative | Negative | Negative | Negative | Negative | Negative | 1.41 U/mL |
Length of antiviral and antibody-based therapy | 10 days | 14 days | 9 days | 10 days | 10 days | 21 days | 20 days | 18 days | 8 days | 7 days |
Length of hospital stay | 14 days | 19 days | 13 days | 28 days | 13 days | 23 days | 43 days | 18 days | 12 days | 17 days |